CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Everolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01931163
NCT01931163Phase 2Completed
CompareCT.gov

Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy

Jenny C. Chang, MD·interventional·Posted Aug 29, 2013·Updated Jul 20, 2021

In Brief

A Phase 2 clinical trial evaluating Everolimus for Breast Cancer and Triple Negative Breast Cancer. Completed, enrolled 24 participants across 3 sites.

Detailed Summary

RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: The purpose of this study is to test how effective combining Cisplatin chemotherapy with Everolimus is in treating subjects with triple negative breast cancer who have residual disease after chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Triple Negative Breast Cancer
CountriesUnited States
CollaboratorsThe Methodist Hospital Research Institute

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 29, 2013
Enrollment StartJul 1, 2013
Primary CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 12.8 years ago

Interventions

Everolimusdrug